Skip to content

7th October 2020

Record number of medical cannabis patients in Australia

Australia’s medical cannabis market experiencing ongoing growth

This September more than 6,000 patients were prescribed medical marijuana treatment through the country’s SAS Category B pathway. This was the highest gain per month ever since the 2016, and it was 18% higher than August of this year, although admittedly the market remains quite small.
Nonetheless there’s noticeable progress and according to North Sydney-based data FreshLeaf Analytics predict that the Australian medical cannabis market will rise to about 95 million Australian dollars in sales of products by 2021.
Record of patients prescribed with medical cannabis in Australia
Also, since currently the products imported from overseas are required to conform with a local law order, they are not always required to be manufactured in a Good Manufacturing Practice-licensed facility, and so the Australian Government is considering mandating that imported medical marijuana meet the GMP quality standards. The Health Department is expected to release consultations on increasing quality requirements for imported cannabis products towards the end of the year.

In November 2019, Medical Cannabiz World opened its doors to the medicinal cannabis industry, supported by the Maltese government’s commitment to legislation for this high growth sector. After last year’s huge success, the second edition of Medical Cannabiz World will take place virtually on the 20th and 21st October 2020. Don’t miss out. Save the dates!